Evaluation of COVID-19 risk in patients on systemic retinoid therapy
Turkderm Turkish Archives of Dermatology and Venereology
; 56(3):109-112, 2022.
Article
in English
| CAB Abstracts | ID: covidwho-2247972
ABSTRACT
Background and Design:
Systemic retinoids are commonly used medications in dermatology and indicated in various skin disorders such as acne vulgaris and psoriasis. Data about the risk of Coronavirus disease-2019 (COVID-19) in patients using systemic retinoids are limited. Thus, this study aimed to investigate the risk of COVID-19 in patients undergoing systemic retinoid therapy. Materials andMethods:
A total of 186 patients who have undergone systemic isotretinoin and acitretin therapy were recruited. Patients who presented to the dermatology clinic for various skin diseases, such as eczema, vitiligo, tinea, etc., who were not on systemic retinoid therapy, and who received topical medications comprised the control group. The development of COVID-19 in the retinoid therapy group and the control group was retrospectively reviewed using hospital database.Results:
The mean age of the patients in the retinoid therapy group was 25.72+or-0.67 and that in the control group was 25.4+or-0.62. Moreover,165 patients received isotretinoin, and 21 patients received acitretin treatment. The isotretinoin dosage ranged from 0.5 to 0.8 mg/kg wheras the acitretin dosage ranged between 10 and 25 mg/day. Two patients (1.07%) in the retinoid therapy group and 8 (4.3%) patients in the control group were diagnosed with COVID-19. None of the patients receiving acitretin was diagnosed with COVID-19. COVID-19 diagnosis was established in the 2nd and 3rd months of isotretinoin treatment, and lung involvement was not observed. No significant difference regarding the number of COVID-19 cases and disease severity was found between the two groups (p=0.105;p=0.258, respectively).Conclusion:
Isotretinoin and acitretin use was not associated with increased COVID-19 risk or disease severity. Systemic retinoids appear to be a safe treatment modality in the COVID-19 era.
Pharmacology [VV730], Prion; Viral; Bacterial and Fungal Pathogens of Humans [VV210], Non-communicable Human Diseases and Injuries [VV600], human diseases, coronavirus disease 2019, viral diseases, pandemics, public health, risk factors, retinoids, drug therapy, skin, skin diseases, psoriasis, acne, eczema, vitiligo, tinea (disease), topical application, case-control studies, retrospective studies, dosage, severe course, safety, acute course, man, Severe acute respiratory syndrome coronavirus 2, Turkey, Homo, Hominidae, primates, mammals, vertebrates, Chordata, animals, eukaryotes, Severe acute respiratory syndrome-related coronavirus, Betacoronavirus, Coronavirinae, Coronaviridae, Nidovirales, positive-sense ssRNA Viruses, ssRNA Viruses, RNA Viruses, viruses, Mediterranean Region, OECD Countries, upper-middle income countries, very high Human Development Index countries, West Asia, Asia, isotretinoin, acitretin, SARS-CoV-2, viral infections, vitamin A compounds, chemotherapy, dermis, dermatoses
Full text:
Available
Collection:
Databases of international organizations
Database:
CAB Abstracts
Type of study:
Experimental Studies
/
Prognostic study
Language:
English
Journal:
Turkderm Turkish Archives of Dermatology and Venereology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS